257 related articles for article (PubMed ID: 28064157)
1. FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII.
Yoon J; Schmidt A; Zhang AH; Königs C; Kim YC; Scott DW
Blood; 2017 Jan; 129(2):238-245. PubMed ID: 28064157
[TBL] [Abstract][Full Text] [Related]
2. Suppression of FVIII-Specific Memory B Cells by Chimeric BAR Receptor-Engineered Natural Regulatory T Cells.
Pohl AP; Venkatesha SH; Zhang AH; Scott DW
Front Immunol; 2020; 11():693. PubMed ID: 32373126
[TBL] [Abstract][Full Text] [Related]
3. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.
Kim YC; Zhang AH; Su Y; Rieder SA; Rossi RJ; Ettinger RA; Pratt KP; Shevach EM; Scott DW
Blood; 2015 Feb; 125(7):1107-15. PubMed ID: 25498909
[TBL] [Abstract][Full Text] [Related]
4. CD4
Fu RY; Chen AC; Lyle MJ; Chen CY; Liu CL; Miao CH
Cell Immunol; 2020 Dec; 358():104216. PubMed ID: 32987195
[TBL] [Abstract][Full Text] [Related]
5. Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells.
Zhang AH; Yoon J; Kim YC; Scott DW
J Immunol; 2018 Sep; 201(5):1434-1441. PubMed ID: 30021767
[TBL] [Abstract][Full Text] [Related]
6. CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII.
Rana J; Perry DJ; Kumar SRP; Muñoz-Melero M; Saboungi R; Brusko TM; Biswas M
Mol Ther; 2021 Sep; 29(9):2660-2676. PubMed ID: 33940160
[TBL] [Abstract][Full Text] [Related]
7. Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo.
Parvathaneni K; Scott DW
Blood Adv; 2018 Sep; 2(18):2332-2340. PubMed ID: 30232086
[TBL] [Abstract][Full Text] [Related]
8. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
Front Immunol; 2021; 12():686439. PubMed ID: 34616392
[TBL] [Abstract][Full Text] [Related]
9. Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.
Becker-Gotot J; Meissner M; Kotov V; Jurado-Mestre B; Maione A; Pannek A; Albert T; Flores C; Schildberg FA; Gleeson PA; Reipert BM; Oldenburg J; Kurts C
J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36107620
[TBL] [Abstract][Full Text] [Related]
10. Reprogrammed CD4
Herzog RW; Kuteyeva V; Saboungi R; Terhorst C; Biswas M
Front Immunol; 2019; 10():274. PubMed ID: 30842776
[TBL] [Abstract][Full Text] [Related]
11. CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice.
Miao CH; Harmeling BR; Ziegler SF; Yen BC; Torgerson T; Chen L; Yau RJ; Peng B; Thompson AR; Ochs HD; Rawlings DJ
Blood; 2009 Nov; 114(19):4034-44. PubMed ID: 19713458
[TBL] [Abstract][Full Text] [Related]
12. Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy.
Parvathaneni K; Abdeladhim M; Pratt KP; Scott DW
Transl Res; 2017 Sep; 187():44-52. PubMed ID: 28651073
[TBL] [Abstract][Full Text] [Related]
13. Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor.
Georgescu MT; Moorehead PC; Liu T; Dumont J; Scott DW; Hough C; Lillicrap D
Front Immunol; 2020; 11():138. PubMed ID: 32117285
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific in vitro expansion of factor VIII-specific regulatory T cells induces tolerance in hemophilia A mice.
Smith BM; Lyle MJ; Chen AC; Miao CH
J Thromb Haemost; 2020 Feb; 18(2):328-340. PubMed ID: 31609041
[TBL] [Abstract][Full Text] [Related]
15. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
16. Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A.
Madoiwa S; Yamauchi T; Kobayashi E; Hakamata Y; Dokai M; Makino N; Kashiwakura Y; Ishiwata A; Ohmori T; Mimuro J; Sakata Y
J Thromb Haemost; 2009 May; 7(5):811-24. PubMed ID: 19220731
[TBL] [Abstract][Full Text] [Related]
17. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
Lei TC; Scott DW
Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
[TBL] [Abstract][Full Text] [Related]
18. Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts.
Su RJ; Epp A; Latchman Y; Bolgiano D; Pipe SW; Josephson NC
Mol Ther; 2010 Jan; 18(1):214-22. PubMed ID: 19755963
[TBL] [Abstract][Full Text] [Related]
19. Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice.
Ramakrishnan R; Davidowitz A; Balu-Iyer SV
J Pharm Sci; 2015 Aug; 104(8):2451-6. PubMed ID: 26038127
[TBL] [Abstract][Full Text] [Related]
20. Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells.
Kim YC; Zhang AH; Yoon J; Culp WE; Lees JR; Wucherpfennig KW; Scott DW
J Autoimmun; 2018 Aug; 92():77-86. PubMed ID: 29857928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
